Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome

• ClinicalTrials.gov Identifier: NCT04565665
• Recruitment Status: Recruiting
• First Posted: September 25, 2020
• Last Update Posted: October 7, 2022
• Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): M.D. Anderson Cancer Center

Tracking Information

• First Submitted Date: September 22, 2020
• First Posted Date: September 25, 2020
• Last Update Posted Date: October 7, 2022
• Actual Study Start Date: July 29, 2020
• Estimated Primary Completion Date: April 30, 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 16, 2021)

• Incidence of composite serious adverse events (Phase I) [ Time Frame: Within 30 days of the first mesenchymal stem cell (MSC) infusion ]
  Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals.
• Patients alive without grade 3, 4 infusional toxicity (Phase II) [ Time Frame: At day 30 post MSC infusion ]
• Patients alive with grade 3 or 4 infusional toxicity (Phase II) [ Time Frame: At day 30 post MSC infusion ]
• Patients not alive (Phase II) [ Time Frame: At day 30 post MSC infusion ]

Original Primary Outcome Measures (submitted: September 24, 2020)

• Incidence of composite serious adverse events (Pilot) [ Time Frame: Within 30 days of the first mesenchymal stem cell (MSC) infusion ]
  Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals.
• Patients alive without grade 3, 4 infusional toxicity (Phase II) [ Time Frame: At day 30 post MSC infusion ]
• Patients alive with grade 3 or 4 infusional toxicity (Phase II) [ Time Frame: At day 30 post MSC infusion ]
• Patients not alive (Phase II) [ Time Frame: At day 30 post MSC infusion ]

Current Secondary Outcome Measures (submitted: April 16, 2021)

• Proportion of successfully extubated patients who present intubated on ventilator support (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Overall survival rate (Phase I) [ Time Frame: At day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Survival rate in patients who present intubated on ventilator support (Phase I) [ Time Frame: At day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I) [ Time Frame: At day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Clinical parameters (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  The effect of MSCs on clinical parameters will be assessed. Continuous clinical parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.
• Oxygenation parameters (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  The effect of MSCs on oxygenation parameters will be assessed. Continuous oxygenation parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.
• Respiratory parameters (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  The effect of MSCs on respiratory parameters will be assessed. Continuous respiratory parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.
• Laboratory markers (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  The effect of MSCs on laboratory markers will be assessed. Continuous laboratory parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.
• Hospitalization stay (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
• Intensive care unit stay (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
• Incidence of infusion-related adverse events (Phase I) [ Time Frame: Up to day 30 post MSC infusion ]
  All grades of infusion-related adverse events will be summarized by grade and type.

Original Secondary Outcome Measures (submitted: September 24, 2020)

• Proportion of successfully extubated patients who present intubated on ventilator support (Pilot) [ Time Frame: Up to day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot) [ Time Frame: Up to day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Overall survival rate (Pilot) [ Time Frame: At day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Survival rate in patients who present intubated on ventilator support (Pilot) [ Time Frame: At day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot) [ Time Frame: At day 30 post MSC infusion ]
  Will be estimated and reported with 95% confidence intervals.
• Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters [ Time Frame: Up to day 30 post MSC infusion ]
  Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
• Hospitalization stay (Pilot) [ Time Frame: Up to day 30 post MSC infusion ]
• Intensive care unit stay (Pilot) [ Time Frame: Up to day 30 post MSC infusion ]
• Incidence of infusion-related adverse events (Pilot) [ Time Frame: Up to day 30 post MSC infusion ]
  All grades of infusion-related adverse events will be summarized by grade and type.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
• Official Title: Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment Acute Respiratory Distress Syndrome
• Brief Summary: This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of COVID-19 related ARDS.

Detailed Description

PRIMARY OBJECTIVE:

I. To assess the safety of administering cord blood derived mesenchymal stem cell (CB-MSC) infusions for treatment of COVID-19 acute respiratory distress syndrome (ARDS).

SECONDARY OBJECTIVES:

I. In the group of patients who present intubated on ventilator support, assess the proportion that are able to be successfully extubated.

II. In the group of patients who present requiring supplemental oxygen but otherwise breathing without assistance, assess the rate of progression to intubation.

III. Estimate the survival rate at day 30 post treatment separately by group.

IV. Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters:

IVa. Resolution of fever. IVb. Changes in oxygen demand (increased oxygen saturation at similar fraction of inspired oxygen [FiO2] or decreased FiO2 requirement).

IVc. Progression to mechanical ventilation. IVd. Length of mechanical ventilation. IVe. Decrease in positive end-expiratory pressure (PEEP) in intubated patients. IVf. Decrease in FiO2 in intubated patients.

V. Determine the treatment effect on laboratory markers:

Va. Complete blood count. Vb. C-reactive protein (CRP). Vc. Ferritin. Vd. D dimer. Ve. Procalcitonin. Vf. Cytokine levels. VI. Estimate hospitalization and intensive care unit (ICU) stay. VII. Report on study related adverse events.

OUTLINE:

Currently not shipping cells outside of MD Anderson Cancer Center in Houston.

PILOT STUDY: Patients receive MSCs intravenously (IV) over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.

PHASE II STUDY: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.

ARM II: Patients receive standard of care.

After completion of study treatment, patients are followed up at days 7, 14, 30, 60, and months 6 and 12.

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• COVID-19 Infection
• COVID-19-Associated Acute Respiratory Distress Syndrome
• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Symptomatic COVID-19 Infection Laboratory-Confirmed

Intervention

• Other: Best Practice
  Receive standard of care
  Other Names:

  • standard of care
  • standard therapy
• Biological: Mesenchymal Stem Cell
  Given IV
  Other Names:

  • Mesenchymal Progenitor Cell
  • MPC

Study Arms

• Experimental: Phase II Arm I (mesenchymal stem cells)
  Patients receive MSCs as in the Pilot study.
  Intervention: Biological: Mesenchymal Stem Cell
• Active Comparator: Phase II Arm II (standard of care)
  Patients receive standard of care.
  Intervention: Other: Best Practice
• Experimental: Pilot study (mesenchymal stem cells)
  Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
  Intervention: Biological: Mesenchymal Stem Cell

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: September 24, 2020): 70
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: April 30, 2023
• Estimated Primary Completion Date: April 30, 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Patients with moderate to severe ARDS per Berlin criteria secondary to COVID-19. Moderate to severe is defined in appendix as the following: moderate partial pressure of arterial oxygen (PaO2)/FiO2 of 100-200 mm Hg, severe PaO2/FiO2 of less than 100 mm Hg
• Negative pregnancy test in a woman with childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
• Patient or legally authorized representative consent
• Because of the nature of COVID-19, patients enrolled on this study with COVID-19 associated ARDS may have been previously enrolled in other Investigational New Drug (IND) trials for their cancer diagnosis or COVID-19. These enrollments will not exclude them from enrollment to this study

Exclusion Criteria:

• Moribund patients not expected to survive up to 48 hours
• Patients with severe chronic liver disease (Childs-Pugh score > 10)
• Pregnant and/or lactating women
• Patients on extracorporeal membrane oxygenation

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Bethany Overman; 713-745-4567; BJSpears@mdanderson.org

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT04565665
• Other Study ID Numbers: 2020-0365; NCI-2020-06741 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); 2020-0365 ( Other Identifier: M D Anderson Cancer Center )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: M.D. Anderson Cancer Center
• Original Responsible Party: Same as current
• Current Study Sponsor: M.D. Anderson Cancer Center
• Original Study Sponsor: Same as current
• Collaborators: National Cancer Institute (NCI)

Investigators

• Principal Investigator: Amanda Olson; M.D. Anderson Cancer Center

• PRS Account: M.D. Anderson Cancer Center
• Verification Date: October 2022